Independent fund research. Built on SEC filings.

How we research funds

ETF · Technology Sector · Invesco

Invesco Biotechnology & Genome ETF (PBE)

Ticker PBE · Since 2005-06-23 · · Holdings as of Jul 31, 2026

Expense ratio
0.59%$59/yr per $10k
5-yr return
+3.4%annualized
1-yr return
+24.7%as of Dec 2025
Net assets
$281.9Mall share classes
Holdings
33

Bottom line

Is PBE a good fund? The bottom line

PBE is an actively managed technology sector ETF from Invesco.

It charges 0.59% — about $59 a year on every $10,000 invested, cheaper than 71% of technology sector funds we track.

It returned +24.7% over one year, +3.4% a year over five years, +5.2% a year over ten (as of Dec 31, 2025, per its prospectus).

With $282 million in net assets and 33 holdings, its largest position is Invesco Private Prime Fund (12.9%) and the top 10 make up 56.8% of the portfolio.

What to watch

  • Concentrated: top 10 holdings are 56.8% of assets
  • High turnover (103% a year) can mean more taxable distributions

Updated Nov 19, 2026

What PBE invests in

The Invesco Biotechnology & Genome ETF (the Fund) seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome Intellidex Index (the Underlying Index).

The Fund is an index fund that seeks to track the investment results of the Underlying Index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC (ICE Data or the Index Provider) compiles and maintains the Underlying Index, which is composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, and are companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. These companies may include biopharmaceutical companies that actively participate in the research and development, animal testing and partial human testing phases of drug development, typically using biotechnological techniques that…

From the fund's prospectus (filed Aug 27, 2026).

PBE performance

Fund calendar-year total returns, 2015–2025 2015: +2.0%; 2016: −23.0%; 2017: +22.4%; 2018: +0.2%; 2019: +18.3%; 2020: +25.5%; 2021: +1.6%; 2022: −10.8%; 2023: +3.7%; 2024: +1.1%; 2025: +24.7% +2% 2015 −23% 2016 +22% 2017 +0% 2018 +18% 2019 +26% 2020 +2% 2021 −11% 2022 +4% 2023 +1% 2024 +25% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
PBE+24.7%+3.4%+5.2%
Technology Sector median+24.0%+10.0%+16.7%

Source: Fund prospectus, as of Dec 31, 2025

Full PBE performance history →

What PBE costs

On a $10,000 investment, PBE's 0.59% expense ratio costs about $59 a year. The prospectus estimates $738 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.

See the full PBE fee table →

PBE top 10 holdings

#Holding% of fund
1Invesco Private Prime Fund12.89%
2Regeneron Pharmaceuticals, Inc.5.47%
3Amgen Inc.5.22%
4CareDx, Inc.5.04%
5Vertex Pharmaceuticals Inc.4.99%
6Invesco Private Government Fund4.97%
7Royalty Pharma PLC4.94%
8Biogen Inc.4.79%
9Gilead Sciences, Inc.4.43%
10United Therapeutics Corp.4.08%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 56.8% of the fund. See all top 25 holdings and asset mix →

Alternatives to PBE

More funds like PBE →

PBE FAQ

What is the expense ratio of PBE?
PBE's expense ratio is 0.59%, which works out to about $59 a year for every $10,000 invested. The prospectus estimates total costs of $738 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is PBE a good investment?
It depends on your goals, but the data points to: concentrated: top 10 holdings are 56.8% of assets; high turnover (103% a year) can mean more taxable distributions. This is general information, not personalized advice.
What does PBE hold?
PBE's largest holdings are Invesco Private Prime Fund (12.9%), Regeneron Pharmaceuticals, Inc. (5.5%), Amgen Inc. (5.2%), CareDx, Inc. (5.0%), Vertex Pharmaceuticals Inc. (5.0%). It holds 33 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is PBE's 5-year return?
PBE returned +3.4% a year over the five years ending Dec 31, 2025, and +5.2% a year over ten years. Past performance does not guarantee future results.
Who manages PBE?
PBE is offered by Invesco through Invesco Exchange-traded Fund Trust.